par Demedts, Ingel I.K.;Van Meerbeeck, Jan P A M J.P.;Awada, Ahmad 
;Berghmans, Thierry
Référence Revue médicale de Bruxelles, 45, 2, page (157-163)
Publication Publié, 2024-03-01
;Berghmans, Thierry Référence Revue médicale de Bruxelles, 45, 2, page (157-163)
Publication Publié, 2024-03-01
Article révisé par les pairs
| Résumé : | All.Can Belgium is a multi-stakeholder, not-for-profit organization dedicated to improving the efficiency of cancer care by putting the needs and well-being of patients at the heart of its priorities. In this spirit, All. Can Belgium brings together healthcare professionals, patient association representatives, policy-makers, researchers and pharmaceutical industry representatives. The last ten years have seen a dramatic evolution in the treatment of patients with lung cancer (BC). To maximize the impact on lung cancer, these therapeutic advances must be accompanied by effective screening, prevention and patient support strategies. Drawing on the joint efforts of healthcare professionals, patient associations, policy-makers and the pharmaceutical industry, All.Can Belgium's Lung Cancer Working Group aims to address the most pressing needs along the therapeutic pathway of lung cancer patients. On November 16, 2023, All. Can Belgium celebrated the official launch of its BC Working Group with a colloquium featuring several conferences on various topics relating to BC and its treatment, supported by patient testimonials. |
